Novavax vaccine over 90% effective in protecting against COVID-19 infection, study shows
Companies, agencies, institutions, etc
COVID-19
NVX
Novavax’s
Erck
the U.S. Food and Drug Administration
Pfizer-BioNTech
Moderna
Johnson & Johnson
the Pfizer-BioNTech and Moderna
J&J
AstraZeneca
Oxford University
the Masimo Foundation for Ethics, Innovation and Competition in Healthcare
The Masimo Foundation
People
Novavax
Stanley Erck
Methodist
Karen Weintraub
Groups
Latin American
African American
Native American
Asian
COVID-19
German
Physical locations
No matching tags
Places
No matching tags
Locations
U.S.
Mexico
Gaithersburg
Maryland
the United Kingdom
the United States
UK
Houston
USA
Novavax
Events
No matching tags
Summary
The government spent $1.2 billion to pre-buy 300 million doses of this vaccine, but the collaborators have not applied for use in the United States, likely because American needs were already met by the first three vaccines to win approval.Related:Pfizer COVID-19 vaccine for younger kids on track, with shots to come in the fall, company saysIn the U.S., Novavax intends its vaccine to mainly be used to provide booster shots if they become necessary, Erck said.
As said here by